Over the past two years, the Spanish Health Ministry has spent 95-110billion pesetas ($732.4-$848.1 million) on the treatment of HIV and AIDS, or equal to around 3% of its total budget, reports the Spanish daily newspaper Cinco Dias.
And in 1997, expenditure on the treatment of this illness will rise another 25 billion pesetas, according to Francisco Parras, general secretary for the country's national AIDS program. This is compared with the 15 billion pesetas that is estimated to have been spent on antiviral treatments in 1996. Of the 25 billion pesetas, 10 billion pesetas will be spent on the cost of the new HIV/AIDS treatments, ie protease inhibitors (Marketletters passim), that have recently become available.
The pharmaceutical companies that manufacture the new treatments, however, point out that the increase in spending now on combination therapy, which includes the protease inhibitors, will result in lower health care spending in the future due to a reduction in hospital stays.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze